Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

    loading  Loading Related Articles